In vitro and Computational Studies of Compounds from Coleus amboinicus against Osteosarcoma

Background

Osteosarcoma (OS) is among the most prevalent primary bone cancers, predominantly affecting children and adolescents. The average prevalent rate of osteosarcoma is 4.3 per million in males and 3.4 per million in females. Osteosarcoma poses diagnostic challenges due to the often-subtle clinical manifestations.

Objectives

To investigate bioactive compounds in Coleus amboinicus Leaves (CAL) using computational methods and predict, their potential interactions with osteosarcoma cell surface receptors to explore therapeutic possibilities.

Materials and Methods

The extract obtained from CAL was analyzed using a phytochemical assay, Fourier-Transform Infrared (FTIR) spectroscopy, and Gas Chromatography-Mass Spectrometry (GCMS). Molecular docking studies were conducted using Autodock to assess the interactions between the components of the extract and the cell surface receptors of osteosarcoma. The molecular docking experiments assessed the affinity of the phytochemicals to particular proteins that have a significant impact on the cell surface receptors of osteosarcoma. The pharmacokinetic characteristics of the drugs were assessed by examining their ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles.

Results

The computer study identified multiple phytochemicals derived from CAL with substantial binding affinity to the proteins of osteosarcoma cell surface receptors. These substances include beta-D-Glucopyranose, 4-O-beta-D-galactopyranosyl, Hexanoic acid, 1-methylethyl ester, and Paromomycin. The ADMET analysis revealed that most of the discovered drugs possess favorable pharmacokinetic features and are anticipated to have low toxicity.

Conclusion

Molecular docking revealed bioactive compounds with strong binding affinity to these receptors, indicating their potential inhibitory effects on cancer cell proliferation. Further research is required to provide comprehensive validation and clinical development.